09.02.2015 • News

BASF to Lift Chromate Pigment Capacities

BASF plans to "significantly increase" production capacities for bismuth vanadate pigments at Besigheim, Germany, near Stuttgart, from 2017.

The German chemical giant markets the yellow pigments with a special greenish color tone used to formulate paints and coatings under the Sicopal and Paliotan brand names.

BASF said its bismuth vanadate pigments are a high performance inorganic alternative to pigments containing lead chromate, which, according to the EU chemicals legislation REACh are classified as CMR substances (carcinogenic, mutagenic or toxic for reproduction).

"Over the next few years we expect our customers' demand for bismuth vanadate pigments to grow faster than the overall pigment market, both in Europe and worldwide. By expanding the production capacities we are responding to this increase in demand," said Alexander Haunschild, senior vice president of BASF's business unit Pigments & Resins Europe.

Starting this year, BASF will no longer produce pigments containing lead chromate. "We are committed to offering our customers innovative products that enable them to develop sustainable solutions," Haunschild stressed.

BASF regards itself as one of the global market leaders in bismuth vanadate pigments. In 2015, it plans to introduce a newly developed alkali-stable bismuth vanadate pigment for the formulation of paints as well as a temperature-stable bismuth vanadate pigment for plastic applications.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read